Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
The primary objective of this study is to describe the transcriptional impact of R178, R257, R40 or A136 variants of the ACTG2 gene on iPS differentiation mechanisms up to organoids derived from PIPO patient samples versus those derived from control / WT patients (generation of IPS from cultured cell lines), at different stages of their experimental ex vivo development.
Full description
Recruited patients will be sampled during a consultation: a blood sample and a biopsy will be taken directly from the patient. Once these samples have been taken, they will be cultured to be reprogrammed into iPS cells, then grown and differentiated into intestinal organoids.
Various experiments will be carried out (as described in the outcomes) to identify at molecular, cellular and tissue level the mechanisms altered in patients with an R178, R257, R40 or A136 variant, assessing their consequence(s) on the development and functionality of the digestive mesenchyme.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
PIPO Population:
WT population:
Exclusion criteria
PIPO population :
Primary purpose
Allocation
Interventional model
Masking
4 participants in 2 patient groups
Loading...
Central trial contact
John Rendu, Dr; Mandy Leger
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal